Study protocol

Design of a placebo-controlled, randomized study of the efficacy of repetitive transcranial magnetic stimulation for the treatment of chronic tinnitus

Michael Landgrebe*1, Harald Binder4, Michael Koller2, Yvonne Eberl2, Tobias Kleinjung3, Peter Eichhammer1, Erika Graf4, Goeran Hajak1 and Berthold Langguth1

Address: 1Department of Psychiatry, Psychosomatics, and Psychotherapy, University of Regensburg, Germany, 2Center for Clinical Studies, University Hospital of Regensburg, Germany, 3Department of Otorhinolaryngology, University Hospital of Regensburg, Germany and 4Institute of Medical Biometry and Medical Informatics, University Medical Center Freiburg, Germany

Email: Michael Landgrebe* - michael.landgrebe@medbo.de; Harald Binder - binderh@fdm.uni-freiburg.de; Michael Koller - michael.koller@klinik.uni-regensburg.de; Yvonne Eberl - Yvonne1.Eberl@klinik.uni-regensburg.de; Tobias Kleinjung - tobias.kleinjung@klinik.uni-regensburg.de; Peter Eichhammer - peter.eichhammer@medbo.de; Erika Graf - erika.graf@uniklinik-freiburg.de; Goeran Hajak - goeran.hajak@medbo.de; Berthold Langguth - berthold.langguth@medbo.de

* Corresponding author

Abstract

Background: Chronic tinnitus is a frequent condition, which can have enormous impact on patient's life and which is very difficult to treat. Accumulating data indicate that chronic tinnitus is related to dysfunctional neuronal activity in the central nervous system. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive method which allows to focally modulate neuronal activity. An increasing amount of studies demonstrate reduction of tinnitus after repeated sessions of low-frequency rTMS and indicate that rTMS might represent a new promising approach for the treatment of tinnitus. However available studies have been mono-centric and are characterized by small sample sizes. Therefore, this multi-center trial will test the efficacy of rTMS treatment in a large sample of chronic tinnitus patients.

Methods/Design: This is a randomized, placebo-controlled, double-blind multi-center trial of two weeks 1 Hz rTMS-treatment in chronic tinnitus patients. Eligible patients will be randomized to either 2 weeks real or sham rTMS treatment. Main eligibility criteria: male or female individuals aged 18–70 years with chronic tinnitus (duration > 6 months), tinnitus-handicap-inventory-score ≥ 38, age-adjusted normal sensorineural hearing (i.e. not more than 5 dB below the 10% percentile of the appropriate age and gender group (DIN EN ISO 7029), conductive hearing loss ≤ 15dB. The primary endpoint is a change of tinnitus severity according to the tinnitus questionnaire of Goebel and Hiller (baseline vs. end of treatment period). A total of 138 patients are needed to detect a clinical relevant change of tinnitus severity (i.e. 5 points on the questionnaire of Goebel and Hiller; alpha = 0.05; 1-beta = 0.80). Assuming a drop-out rate of less than 5% until the primary endpoint, 150 patients have to be randomized to guarantee the target number of 138 evaluable patients. The study will be conducted by otolaryngologists and psychiatrists of 7 university hospitals and 1 municipal hospital in Germany.

Discussion: This study will provide important information about the efficacy of rTMS in the treatment of chronic tinnitus.

Trial registration: Current Controlled Trials ISRCTN89848288
Background
Subjective tinnitus is a frequent auditory sensation experienced in the absence of an external or internal acoustic stimulus. Tinnitus may present only sporadically or may manifest as constant ear-ringing of high intensity that entrains significant morbidity and may progress to a chronic debilitating condition. There is increasing evidence from electrophysiological and functional neuroimaging studies that tinnitus results from increased neuronal activity within the central auditory pathways [1]. Similar like in auditory hallucinations [2] the increased neuronal firing in the auditory cortex results in the perception of a phantom sound. This notion is supported by recent neuroimaging studies which point to a pathologically over activated, distributed cortical network involving the inferior colliculus [3], the thalamus [4], and the primary auditory cortex [4-7] in subjects with tinnitus. The pathophysiological relevance of this network has been demonstrated recently by transient suppression of tinnitus after high-frequency rTMS to the temporal and temporo-parietal cortex [8,9].

Low-frequency rTMS (1 Hz) is known to reduce neural activity in directly stimulated brain regions [10,11] as well as in structurally connected remote brain regions [11,12]. For these reasons low-frequency rTMS has been proposed as an innovative and causally orientated treatment strategy for pathological conditions with increased cortical activity [13]. Consequently, applied to the left temporo-parietal cortex rTMS has been repeatedly demonstrated to reduce auditory hallucinations in patients with schizophrenia [14].

In pilot studies, first evidence for a beneficial effect of magnetic resonance imaging (MRI) and positron emission tomography (PET) guided neuronavigated low-frequency rTMS has been found in patients with chronic tinnitus [15]. This finding has been confirmed by several controlled trials which all demonstrated a significant reduction of tinnitus severity after five to ten days of active rTMS as compared to sham stimulation [16-18]. Neurophysiological work could recently detect that rTMS-induced improvement in tinnitus complaints was paralleled by changes in cortical excitability, suggesting, that this beneficial therapeutical effect is associated with the induction of neuroplastic processes [19]. In line with these data, neuroimaging studies using voxel-based morphometry (VBM) demonstrated that low-frequency rTMS over auditory brain regions is able to induce profound changes in gray matter both in cortical auditory brain areas as well as in the thalamus [12]. Since neuroplastic alterations at the level of the thalamus seem to be essential in the generation of chronic tinnitus [20], low-frequency rTMS may represent a new approach for treating this disorder by inducing neuroplasticity in selective cortical networks closely linked to its pathogenesis. The use of rTMS in chronic tinnitus is further supported by studies showing that rTMS has beneficial effects in a variety of neuropsychiatric disorders associated with focal hyperexcitability such as focal dystonias, focal epilepsy and post-traumatic stress disorder [11,21,22].

Taken together, a multitude of studies indicate a potential of low-frequency rTMS for the treatment of auditory phantom perceptions. With regard to chronic tinnitus, especially imaging guided rTMS has been proven to be beneficial in the treatment of chronic tinnitus. Since neuronavigated rTMS is sophisticated, costly and time consuming this kind of application is strongly limited and not applicable in routine activity. Due to these considerations, a simple and reliable method for stimulating the auditory cortex based on the 10–20 EEG system has been recently developed [23] and will be used in the present trial. Furthermore, studies so far investigated only relatively small populations. Therefore, in order to render rTMS as an effective treatment according to the principle of evidence based medicine, it is necessary to assess the efficacy of this treatment in a properly designed and conducted randomized-controlled trial in a large patient sample.

Methods
Design of the trial
This is a multicenter, randomized, patient and observer-blind, sham-controlled, parallel-group study of 2 weeks 1 Hz rTMS treatment plus 24 weeks follow-up in patients with moderate to severe chronic tinnitus. Eligible patients will be randomly assigned to either 2 weeks real rTMS treatment or sham treatment (figure 1).

Study population
Female and male subjects aged 18 to 70 years are eligible for study participation if they meet the following criteria:

Inclusion criteria
- Written informed consent
- Diagnosis of chronic tinnitus
- Patient has a score of ≥ 38 on the Tinnitus Handicap Inventory (assessed during routine clinical diagnostics in the last 12 weeks before start of treatment)
- Tinnitus duration of more than 6 months
- Age-adjusted normal sensorineural hearing determined by an audiogram within the last 12 weeks before start of treatment, i.e. no more than 5 dB below the 10 % percentile (DIN EN ISO 7029) of the appropriate age and gender group in all measured standard frequencies.
no conductive hearing loss of more than 15 dB in neither of the measured standard frequencies.

- naïve regarding rTMS

**Exclusion criteria**

- Objective Tinnitus
- Other forms of tinnitus treatments at the same time
- Clinically relevant psychiatric co-morbidity as judged by an experienced psychiatrist, especially diagnose groups F1-3 according to the International Classification of diseases (ICD-10)
- Concomitant treatment with psychotropic drugs
- History or evidence of significant brain malformation or neoplasm, head injury, cerebral vascular events, neurodegenerative disorder affecting the brain or prior brain surgery
- Severe unstable somatic co-morbidity
- Cardiac pace makers, other electronic implants, intracranial metallic particles
- History of seizures or epileptic activity
- Pregnancy and lactation
- Women in child-bearing-age without contraception
- Patients who cannot communicate reliably with the investigator or who are not likely to cope with the requirements of the trial
- Participation in a clinical trial within the last 30 days before start of this clinical trial

**Participating centers**

This study will be conducted by otorhinolaryngologists and psychiatrists with wide experience in the treatment of patients with chronic tinnitus from seven university hospitals and one municipal hospital all over Germany. All participating centers have experience in conducting rTMS-treatment studies.

**Study treatments**

Screening is performed during the routine clinical tinnitus-consultations, and no additional study specific investigations are necessary to determine eligibility. After screening, written informed consent, baseline assessments, and randomization, patients will be treated with either real or sham low-frequency rTMS over a period of 2 weeks. rTMS will be administered according to current safety guidelines [24]. Magstim Super Rapid (The Magstim Company Ltd, Whitland, UK) or Medtronic MagPro (Medtronic GmbH & Co. KG, Düsseldorf, Germany) stimulators will be used for stimulation as available in the participating centers. Figure-of-eight-coils will be used for real stimulation. Sham stimulation will be carried out by tilting the coil 45° away from the skull with one wing touching the skull. The stimulation parameters have been chosen according to successful pilot studies [15,25] and modified with respect to duration, coil positioning and control condition. Recent data point to a dose-response relationship of rTMS treatment in a variety of neuropsychiatric diseases as well as in tinnitus treatment [23,26]. Furthermore, coil positioning using the 10–20 EEG-system has been proven to guarantee exact placement of the TMS coil over the auditory cortex without the need of using MR- and PET-guidance. Finally, finding an adequate placebo condition [27] is still under debate in clinical rTMS studies [28]. Here, sham stimulation will be performed by distortion of the magnetic coil 45° away from the skull with one wing touching the skull. In contrast to sham coils, this kind of sham stimulation does not induce a sufficiently strong magnetic field in the brain tissue to evoke any biological response but is still eliciting some kind of skull sensation. Especially in the context of tinnitus treatment studies, controlling for somatosensory stimulation seems to be critical since somatosensory input is able to modulate tinnitus sensation [1].

After screening, written informed consent, and baseline assessments, patients will be randomized to one of two parallel groups with the following stimulation parameters:

**Treatment group** will receive real stimulation: 2 × 5 sessions, 1 Hz rTMS, stimulation intensity 110% related to the individual resting motor threshold, 2000 stimuli per session, coil position 10–20 guided over left primary auditory cortex.

**Control group** will receive sham stimulation by distortion of the magnetic coil 45° away from the skull with one wing touching the skull.
wing touching the skull. Coil positioning and stimulation parameters as in the treatment group.

At the beginning of the first treatment session, the individual resting motor threshold for the right abductor pollicis brevis muscle of each participant will be determined according to [29].

**Blinding**

As already mentioned, blinding constitutes a substantial methodological challenge in rTMS studies. Therefore, a blinded design will be applied, in which patients and clinical raters will be blind to treatment conditions (observer blind). rTMS treatment will be provided by the non-blinded study staff. Patients have to be naïve regarding rTMS treatment and will not be informed about technical details of rTMS application. As the non-blinded study staff applying rTMS treatment needs to know whether real or sham rTMS is to be applied, and automatic rTMS is methodologically not feasible in clinical settings to date, the non-blinded study staff applying rTMS will be instructed not to communicate the treatment arm to anybody involved in patient management, in order to prevent any impact on blinding. The investigators performing all other assessments will be experienced physicians, not involved in rTMS treatment of the patient, and will perform all study specific procedures, e.g. getting informed consent, handing out clinical questionnaires or discussing any details about the conduct of the study with the patients. To assess successful blinding of the trial, each patient will be asked at the final visit (V14, day 181) whether or not he or she guesses to have been treated with real or sham rTMS.

**Objectives**

**General objective**

Aim of this trial is to evaluate the efficacy of low-frequency rTMS in the treatment of chronic tinnitus. Based on the findings in pilot studies we hypothesize that two weeks treatment of low-frequency rTMS is more efficient in alleviating symptoms of chronic tinnitus and improving secondary symptoms like quality of life, cognitive functioning or depressive symptoms than sham treatment.

**Primary objective**

To evaluate the efficacy of real rTMS versus sham rTMS in the treatment of chronic tinnitus by means of a change of tinnitus severity according to the tinnitus questionnaire of Goebel & Hiller ([30], a self-rating questionnaire; baseline versus day 12).

**Secondary objectives**

To evaluate the efficacy of real rTMS versus sham rTMS - in reducing tinnitus severity according to the tinnitus questionnaire of Goebel & Hiller and Tinnitus Handicap Inventory (THI; a self-rating questionnaire; [31]) during the follow-up period (screening versus baseline versus days 5, 12, 18, and weeks 10 and 26),

- in changes of quality of life of patients as measured by the SF 12 (a self-rating questionnaire [32]; baseline versus days 5, 12, 18, and weeks 10 and 26),

- in changes of depressive symptoms as measured by the Beck Depression Inventory (BDI; a self-rating questionnaire; [33]; baseline versus days 5, 12, 18, and weeks 10 and 26),

- in changes of psychometric parameters of tinnitus (tinnitus minimal masking level and tinnitus loudness) as assessed by audiological evaluation (screening versus day 18),

- in changes of structural and functional neuroplastic adaption processes as detected by voxel-based morphometry (VBM) and paired-pulse TMS (baseline versus day 12).

**Adjunctive measures**

Further important factors that may influence treatment outcome may be clinical characteristics [34], the individual psychic resilience and personality traits. These will be assessed by using the German versions of the Tinnitus Sample Case History Questionnaire ([35]; please see also the URL in the Availability and requirements section), the NEO-FFI (a validated self-report questionnaire for measurement of the Five Factor model basic personality traits, neuroticism, extraversion, openness to experience, agreeableness, and conscientiousness; [36]) and the RS-11 (a patient self-rating to determine psychic resilience [37]).

**Enhancing quality of outcome measures**

Tinnitus is a subjective sensation that cannot be measured by any objective parameter. Therefore, validated self rating scales (Tinnitus Handicap Inventory (THI) [31] and Tinnitus Questionnaire of Goebel and Hiller (TQ) [30]) are the only instruments to assess changes in tinnitus symptoms. Furthermore, tinnitus symptoms are often fluctuating and are influenced by attention. To minimize biases by spontaneous fluctuations or interactions with the trial staff, the rating scales will be handed out to the patient at the beginning of each visit before any other action will be taken. The patient should be seated in a quiet, comfortable room without any disturbances while answering the questionnaires. Furthermore, to increase the stability of the baseline measurement, tinnitus specific assessments (TH1 and TQ) will be performed three times (at the baseline visit and two times during the baseline
week over three measurements will be used as baseline value.

**Determination of sample size**

Based upon our clinical experience, a difference of 5 points in tinnitus score (range: 0 – 80) according to the TQ is both clinically relevant and observable in a study setting [34], and 0.486 is a conservative estimate of the effect size [15,23,25,34]. Requiring a power (1-\(\beta\)) of 0.80 for detection of such an effect with a two-sided unpaired t-test (at a level of \(\alpha = 0.05\)) leads to a sample size of 68 per arm (active vs. sham). A simulation study was conducted based on the pilot data, to study possible implications of incorporating center effects and baseline levels in the analysis, in which it was confirmed that the planned analysis of covariance indeed provided a power of about 0.80, given a sample size of 136. To account for the possibility of a substantially larger effect size, a scheduled interim-analysis will be carried out at the 50% recruitment level, so that a 138 subjects are needed in total (see e.g. [38]). Assuming that less than 5 percent of patients will fail to provide post-baseline data, 150 patients will be randomized to make sure that the target number of 138 evaluable patients will be reached.

**Randomization**

Before the trial starts, randomization lists will be generated by the Clinical Trials Center, University Medical Center Freiburg, with a 1:1 treatment ratio, stratified by study center and with randomly varying block sizes. At each center, local investigators will have to confirm eligibility of enrolled patients and the non-blinded study staff will forward their request for randomization by fax to the randomization center, located at the department of the lead investigator. There, the randomization lists will be securely stored with none of the clinical staff involved in the trial having access to it. The randomization center will send the allocated treatment by fax to the local non-blinded staff performing rTMS. In addition, a standard email including a statement that the patient has been successfully randomized, will be send to both, the blinded and non-blinded study staff of the center as well as to the monitor.

**Statistical Analysis**

The primary endpoint for evaluation of efficacy of rTMS for tinnitus is the change from baseline to day 12 in the tinnitus score (TQ total score). The treatment effect will be estimated on an intention-to-treat basis including all patients with post-baseline data (carrying forward day 5 measurements if day 12 is missing), in an analysis of covariance including treatment and average baseline score as fixed factors and center as a random factor. Interim analysis for TQ change at day 12 will be carried out on the first 76 randomized patients following an O’Brien and Flem-
on any adverse event, including side effects of study treatments, will be collected during the treatment period (visits 2 – 11). An independent data safety and monitor board (DSMB) consisting of clinical and statistical experts will critically assess adherence to the study protocol as well as to ICH-GCP-guidelines. Together with the sponsor, the DSMB will decide whether the trial has to be terminated prematurely. Possible reasons encompass e.g. safety concerns, unexpected high discontinuation rates or a large effect size on TQ at day 12 determined by the interim analysis.

**Timing**

The start of the study is February 2008. With a planned number of 138 patients providing post-baseline data, a drop out rate for the primary outcome of less than 5% and an expected screening to inclusion ratio of 5:1, 750 patients will have to be assessed for eligibility in all 8 centers, and 150 will be allocated for trial participation. The recruitment and treatment period will be 27 months, with 6 additional months to complete follow-up. Analyses and reporting will be estimated to be 6 months, resulting in a total duration of about 3 years.

### Table 1: Study Plan

| Visits | V0 | V1 | V2 | V3 | V4 | V5 | V6 | V7 | V8 | V9 | V10 | V11 | V12 | V13 | final visit |
|--------|----|----|----|----|----|----|----|----|----|----|-----|-----|-----|-----|------------|
| **Week** | Screening | Baseline | R | Treatment | Follow-Up |
| **Day** | Week 0 | Week 1 | Week 2 | Week 3 | Week 10 | Week 26/PTV |
| Rating Scales (THI) | X<sup>1</sup> | X<sup>2</sup> | 1 to -9 | 2 | 3 | 4 | 5 | 8 | 9 | 10 | 11 | 12 | 17 – 19 | 66 – 68 | 180 – 182 |
| Otologic examination and audiological assessment | X<sup>1</sup> | | |
| Informed Consent | X | |
| Demographic Data | X | |
| Medical History | X | |
| Documentation of Comorbidity | X | X | X | X | X | |
| Documentation of concomitant medication | X | X | X | X | X | |
| Physical examination | X | X | X | X | |
| Vital Signs | X | X | X | X | X | |
| Rating Scales (Goebel&Hiller, BDI, SF 12) | X<sup>2</sup> | X | X | X | X | X | |
| Tinnitus-Severity | X | X | X | X | X | X | |
| NEO FFI, RS-11 | X | X | X | X | X | |
| CGI | X | X | X | X | X | X | X | |
| Neuropsychological Assessment | X | X | X | X | X | |
| Cortical Excitability (pTMS) | X | | X | X | |
| Structural Neuroimaging (VBM) | X | X | X | X | |
| Inclusion/Exclusion | X | X | X | X | X | X | X | |
| Randomization | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | |

<sup>1</sup> = results of routine clinical investigations
<sup>2</sup> = each patient receives at V1 two versions of THI and TQ to be completed on Monday and Friday before V2
<sup>3</sup> = randomisation
<sup>4</sup> = Visit 14 or PTV = Premature Termination Visit
**Ethical aspects**

*Safety of rTMS*

Applied under previously published safety guidelines [24], rTMS has been proven to be a safe and well tolerated therapy in a broad range of studies encompassing distinct neuropsychiatric diseases. Considerable side effects of rTMS encompass potentially occurring physical discomfort on the scalp during stimulation and headache after rTMS with an incidence of about 5%. Other relevant side effects are not expected if known contraindications (see exclusion criteria) are respected.

*Ethics committee*

The study protocol as well as the documents to obtain patient’s informed consent have been approved by the independent ethics committee of the coordinating center at the university of Regensburg on October 24th 2006. The study will be performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki and are consistent with the ICH guidelines for Good Clinical Practice. The trial has been registered at the International Standard Randomized Controlled Trial Number Registration (ISRCTN89848288).

*Patient information and informed consent*

The patient will be fully informed about the nature, purpose, possible risks and benefit of the study by the investigator before any study specific actions will take place. Patients will be notified that they are free to discontinue from the study at any time without any disadvantages for further clinical care. There will be sufficient time to ask questions and to consider the information provided. If the patient is willing to participate in the trial, he or she will be asked to sign the informed consent form. Patients must be withdrawn from study treatment when judged necessary by the investigator. Reasons may be for example safety concerns, severe non-compliance, incorrect enrolment or randomization. Follow-up will end in case of withdrawal of the informed consent by the patient.

*Data management*

Data management will be performed by the Center for Clinical Studies, University of Regensburg. An Access database will be used and after closure of the database, data will be transferred to the Clinical Trials Center, University Medical Center Freiburg for data analysis.

*Monitoring*

Monitoring will be performed according to current ICH-GCP-guidelines. Each center will be initiated by a standardized conference call using a presentation describing the basic principles of the study and most relevant procedures (e.g. getting informed consent, randomization, treatment procedures, emergency unblinding). In addition, each center will be visited regularly by the monitor depending on the patient recruitment.

**Discussion**

Although chronic tinnitus is a frequent and often disabling condition, no treatment can yet be considered well established in terms of providing replicable long-term reduction of tinnitus impact in excess of placebo effects [39]. Therefore, new therapeutic approaches are highly needed. Based on recent advances in the understanding of the pathophysiology of tinnitus and based on an increasing amount of promising pilot data, rTMS seems to hold high potential as a new treatment tool. However, clinical data on the efficacy are limited, mainly due to the small sample sizes of available studies. Several methodological difficulties had to be considered in the design of this trial. First tinnitus is a purely subjective phenomenon, which is difficult to assess. Second, only recently an expert consensus for treatment outcome measurements in tinnitus patients has been published [35]. Third the blinding condition is more difficult to perform in rTMS studies than in pharmacologic studies and fourth there is only very limited experience with multi-center placebo-controlled trials conducted according to ICH-GCP guidelines for both the indication tinnitus and the intervention rTMS.

Here we present a study protocol for a multi-center, placebo-controlled clinical rTMS trial conducted according to ICH-GCP guidelines and to the above mentioned expert consensus [35] and involving professional monitoring. The presented study protocol takes into account all the described methodological difficulties and demonstrates the feasibility of a controlled multi-center rTMS trial thereby enhancing the quality of the collected data. The study sample is one of the largest ever investigated in TMS studies and the largest sample of patients with chronic tinnitus.

**Abbreviations**

BDI: Beck Depression Inventory; DSMB: Data Safety Monitor Board; GCP: Good Clinical Practice; ICH: International Conference on Harmonization; LOCF: last observation carried forward; MR: magnet resonance tomography; NEO FFI, NEO: Five Factor Inventory; RTMS: repetitive transcranial magnetic stimulation; THI: Tinnitus Handicap Inventory; TQ: Tinnitus Questionnaire of Goebel&Hiller; VBM: Voxel-based Morphometry; RS-11: short for of the German questionnaire to assess resilience; SF 12: Quality of life assessment scale.

**Availability and requirements**
Tinnitus Sample Case History Questionnaire (German, English, French, Italian, Spanish, Dutch, Czech, Portuguese):

http://www.tinnitusresearch.org/en/consensus/consensus_en.php

Competing interests
The author(s) declare that they have no competing interests.

Authors’ contributions
ML, MK, TK, PE, GH and BL contributed to the design of the study. The study protocol has been written by ML, PE and BL, the manuscript has been drafted by ML and BL. Responsible for recruitment and follow-up of the enrolled patients as well as coordination of the multi-center trial will be ML and BL. The statistical design and all statistical analyses will be performed by HB and EG.

Monitoring
Dr. J. Reisinger, multi-service-monitoring, Regensburg, Germany

Trial coordinating center
University of Regensburg, Prof. Dr. G. Hajak (Principal Investigator), Department of Psychiatry. Center for Clinical Studies of the University of Regensburg, Prof. Dr. M. Koller (data management).

Acknowledgements
This study is granted by the German Research Foundation (DFG; HA 3547/4-1).

References
1. Moller AR: Pathophysiology of tinnitus. Otologyng Clin North Am 2003, 36:249-66.
2. Hoffman RE, Quegevireu R, Hawkins KA, Varanko M, Boutros NN, Wu YT, Carroll K, Krystal JH: Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biol Psychiatry 2005, 58:97-104.
3. Melcher JR, Sigalovksy IS, Guinan JJ Jr, Levine RA: Lateralized tinnitus studied with functional magnetic resonance imaging: abnormal inferior colliculus activation. J Neurophysiol 2000, 83:1058-1072.
4. Reyes SA, Salvi RJ, Burkard RF, Coad ML, Wack DS, Galantowicz PJ, Lockwood AH: Brain imaging of the effects of lidocaine on tinnitus. Hear Res 2002, 171:43-50.
5. Arnold W, Bartenstein P, Oestreich E, Römer W, Schwäger M: Focal metabolic activation in the predominant left auditory cortex in patients suffering from tinnitus: a PET study with [18F]deoxyglucose. ORL J Otorhinolaryngol Relat Spec 1996, 58:195-199.
6. Mizr F, Pedersen B, Ishizu K, Johanssen P, Ovesen T, Stokilde-Jørgensen H, Gjedde A: Positron emission tomography of cortical centers of tinnitus. Hear Res 1999, 134:133-144.
7. Lockwood AH, Salvi RJ, Burkard RF, Galantowicz PJ, Coad ML, Wack DS: Neuroanatomy of tinnitus. Scand Audiol Suppl 1999, 51:47-52.
8. Plewnia C, Bartels M, Gerloff C. Transient suppression of tinnitus by transcranial magnetic stimulation. Ann Neuro 2003, 53:263-266.
9. De Ridder D, Verstraeten E, Van der KK, De Mudder G, Sunaert S, Verlooy J, Van de HP, Moller A: Transcranial magnetic stimulation for tinnitus: influence of tinnitus duration on stimulation parameter choice and maximal tinnitus suppression. Otol Neurotol 2005, 26:616-619.
10. Chen R, Classen J, Gerloff C, Celnik P, Wassermann EM, Hallett M, Cohen LG: Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation. Neurology 1997, 48:1398-1403.
11. Siebner HR, Filipovic SR, Rowe JB, Cordivari C, Gerschlager W, Rotherwell J, Frackowiak RS, Bhatia KP: Patients with focal arm dystonia have increased sensitivity to slow-frequency repetitive TMS of the dorsal premotor cortex. Brain 2003, 126:2710-2725.
12. Muhlau M, Rauschecker JP, Oestreicher E, Gaser C, Rottinger M, Wohlschlager AM, Simon F, Etgen T, Conrad B, Sander D: Long-term effects of repetitive transcranial magnetic stimulation in schizophrenia. Lancet 2000, 355:1073-1075.
13. Plewnia C, Reimold M, Najib A, Reischl G, Piontek SK, Gerloff C: Moderate therapeutic efficacy of positron emission tomography-navigated repetitive transcranial magnetic stimulation for chronic tinnitus: a randomised, controlled pilot study. J Neurol Neurosurg Psychiatry 2007, 78:152-156.
14. Rossi S, De CA, Ulivelli M, Bartalini S, Falzarano V, Filippone G, Pascero S: Effects of repetitive transcranial magnetic stimulation on chronic tinnitus. A randomised, cross over, double blind, placebo-controlled study. J Neurol Neurosurg Psychiatry 2007.
15. Smith JA, Menneemeier M, Bartel T, Chelette KC, Kimbrell T, Triggs W, Dornhoffner JL: Repetitive transcranial magnetic stimulation for tinnitus: a pilot study. Laryngoscope 2007, 117:529-534.
16. Langguth B, Kleinjung T, Marienhagen J, Binder H, Sand PG, Hajak G, Eichhammer P: Transcranial magnetic stimulation for the treatment of tinnitus: effects on cortical excitability. BMC Neurosci 2007, 8:45.
17. Danner P, Oesterreich E, Gasser C, Rottinger M, Wohlschlager AM, Simon F, Etgen T, Conrad B, Sander D: Structural brain changes in tinnitus. Cereb Cortex 2006, 16:1283-1288.
18. Grisaru N, Amir M, Cohen H, Kaplan Z: Effect of transcranial magnetic stimulation in posttraumatic stress disorder: a preliminary study. Biol Psychiatry 1998, 44:52-55.
19. Tergau F, Naumann U, Paulus W, Steinhoff BJ: Low-frequency repetitive transcranial magnetic stimulation improves intractable epilepsy. Lancet 1999, 353:2209.
20. Langguth B, Zowe M, Landgrebe M, Sand P, Kleinjung T, Binder H, Hajak G, Eichhammer P: Transcranial magnetic stimulation for the treatment of tinnitus: a new coil positioning method and first results. Brain Topography 2006, 18:241-247.
21. Wassermann EM: Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5–7, 1996. Electroencephalogr Clin Neurophysiol 1998, 108:1-16.
22. Kleinjung T, Eichhammer P, Langguth B, Hajak G, Wolf SR, Strutz J: Long-term effects of repetitive transcranial magnetic stimulation (rTMS) in patients with chronic tinnitus. Otolaryngol Head Neck Surg 2005, 132:566-569.
23. Gershon AA, Dannon PN, Grunhaus L: Transcranial magnetic stimulation in the treatment of depression. Am J Psychiatry 2003, 160:835-845.
24. Friedman LM, Furrberg CD, DeMets DL: Blindness. In Fundamentals of Clinical Trials 3rd edition. Edited by: Friedman LM, Furrberg CD, DeMets DL. New York: Springer Science+Business Media; 1998:82-92.
field and the induction of motor-evoked potentials. Biol Psychiatry 2001, 49:460-463.
29. Rossini PM, Barker AT, Berardelli A, Caramia MD, Caruso G, Cracco RQ, Dimitrijevic MR, Hallett M, Katayama Y, Lucking CH, Maertens de Noordhout AL, Marsden CD, Murray NMF, Rothwell JC, Swash M, Tomberg C. Non-invasive electrical and magnetic stimulation of the brain, spinal cord and roots: basic principles and procedures for routine clinical application. Report of an IFCN committee. Electroencephalogr Clin Neurophysiol 1994, 91:79-92.
30. Hiller W, Goebel G. A psychometric study of complaints in chronic tinnitus. J Psychosom Res 1992, 36:337-348.
31. Newman CW, Jacobson GP, Spitzer JB. Development of the Tinnitus Handicap Inventory. Arch Otolaryngol Head Neck Surg 1996, 122:143-148.
32. Bullinger M, Kirchberger I. SF-12. Göttingen, Hogrefe; 1998.
33. Beck AT, Steer RA. Internal consistencies of the original and revised Beck Depression Inventory. J Clin Psychol 1984, 40:1365-1367.
34. Kleinjung T, Steffens T, Sand P, Murthum T, Hajak G, Strutz J, Langguth B, Eichhammer P. Which tinnitus patients benefit from transcranial magnetic stimulation? Otolaryngol Head Neck Surg 2007, 137:589-595.
35. Langguth B, Goodey R, Azevedo A, Bjorne A, Cacace A, Crocetti A, Del BL, De RD, Diges I, Elbert T, Flor H, Herraiz C, Ganz Sanchez T, Eichammer P, Figueiredo R, Hajak G, Kleinjung T, Landgrebe M, Londero A, Lainez MJa, Mazzoli M, Meikle MB, Melcher J, Rauschecker JP, Sand PG, Struve M, van de Heyning P, van Dijk P, Vergara R. Consensus for tinnitus patient assessment and treatment outcome measurement: Tinnitus Research Initiative meeting, Regensburg, July 2006. Prog Brain Res 2007, 166:525-536.
36. Costa PT, McCrae RR. Neo-Fünffaktoren-Inventar (NEO-FFI), ins Deutsche übersetzt von Borkenau P, Ostendorf F. Göttingen: Hogrefe; 1993.
37. Schumacher J, Leppert K, Gunzelmann T, Struß B, Braehler E. Die Resilienzskala – Ein Fragebogen zur Erfassung der psychischen Widerstandsfähigkeit als Personmerkmal. Z Klin Psychol Psychiatr Psychother 2005, 53:16-39.
38. Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials. Boca Raton/Florida: Chapman&Hall/CRC; 2000.
39. Dobie RA. A review of randomized clinical trials in tinnitus. Laryngoscope 1999, 109:1202-1211.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-244X/8/23/prepub